Patent 9676756 was granted and assigned to Portola Pharmaceuticals on June, 2017 by the United States Patent and Trademark Office.
Provided are substituted pyrimidinyl compounds for inhibition of JAK and/or Syk kinase, pharmaceutical compositions thereof, methods for inhibiting JAK and/or Syk kinase activity, and methods for treating conditions mediated at least in part by JAK and/or Syk kinase activity.